复发/难治性b细胞急性淋巴细胞白血病患者对blinatumumab和inotuzumab ozogamicin治疗的反应特点

Q4 Medicine

Cellular Therapy and Transplantation Pub Date : 2020-04-28 DOI:10.18620/ctt-1866-8836-2020-9-1-47-52

I. Markova, S. Bondarenko, O. Paina, B. Aubova, P. Kozhokar, A. Frolova, I. Barkhatov, E. Babenko, Alexander A Alyanskiy, K. Ekushov, T. Gindina, E. Semenova, I. Moiseev, L. Zubarovskaya, B. Afanasyev

{"title":"复发/难治性b细胞急性淋巴细胞白血病患者对blinatumumab和inotuzumab ozogamicin治疗的反应特点","authors":"I. Markova, S. Bondarenko, O. Paina, B. Aubova, P. Kozhokar, A. Frolova, I. Barkhatov, E. Babenko, Alexander A Alyanskiy, K. Ekushov, T. Gindina, E. Semenova, I. Moiseev, L. Zubarovskaya, B. Afanasyev","doi":"10.18620/ctt-1866-8836-2020-9-1-47-52","DOIUrl":null,"url":null,"abstract":"included 182 patients with r/r B-ALL, their age was from one to 72 years old. 128 patients were treated with blinatumomab, 54 patients received inotuzumab ozogamicin. Overall response was high in both groups, 96 (75%) and 44 (82%). Th e major predictors of response were adult age (OR= 3.819; 95% CI, 1.744-8.223; p=0.001) and clinical indications, i.e., active disease or measurable residual disease (OR= 0.018; 95% CI, 0.153-0.841; p=0.01). Th e other clinical or disease parameters had no signifi cant impact on response. Features of response to blinatumomab and inotuzumab ozogamicin therapy in patients with relapse/refractory B-cells acute lymphoblastic leukemia in real clinical practice. Cell Th er Transplant 9(1):","PeriodicalId":39111,"journal":{"name":"Cellular Therapy and Transplantation","volume":"28 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Features of response to blinatumomab and inotuzumab ozogamicin therapy in patients with relapse/refractory B-cells acute lymphoblastic leukemia in real clinical practice\",\"authors\":\"I. Markova, S. Bondarenko, O. Paina, B. Aubova, P. Kozhokar, A. Frolova, I. Barkhatov, E. Babenko, Alexander A Alyanskiy, K. Ekushov, T. Gindina, E. Semenova, I. Moiseev, L. Zubarovskaya, B. Afanasyev\",\"doi\":\"10.18620/ctt-1866-8836-2020-9-1-47-52\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"included 182 patients with r/r B-ALL, their age was from one to 72 years old. 128 patients were treated with blinatumomab, 54 patients received inotuzumab ozogamicin. Overall response was high in both groups, 96 (75%) and 44 (82%). Th e major predictors of response were adult age (OR= 3.819; 95% CI, 1.744-8.223; p=0.001) and clinical indications, i.e., active disease or measurable residual disease (OR= 0.018; 95% CI, 0.153-0.841; p=0.01). Th e other clinical or disease parameters had no signifi cant impact on response. Features of response to blinatumomab and inotuzumab ozogamicin therapy in patients with relapse/refractory B-cells acute lymphoblastic leukemia in real clinical practice. Cell Th er Transplant 9(1):\",\"PeriodicalId\":39111,\"journal\":{\"name\":\"Cellular Therapy and Transplantation\",\"volume\":\"28 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cellular Therapy and Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18620/ctt-1866-8836-2020-9-1-47-52\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Therapy and Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18620/ctt-1866-8836-2020-9-1-47-52","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

摘要

纳入182例r/r B-ALL患者，年龄1 ~ 72岁。128例患者接受blinatumab治疗，54例患者接受inotuzumab ozogamicin治疗。两组患者的总有效率均较高，分别为96(75%)和44(82%)。反应的主要预测因素为成人年龄(OR= 3.819;95% ci, 1.744-8.223;p=0.001)和临床适应症，即活动性疾病或可测量的残留疾病(or = 0.018;95% ci, 0.153-0.841;p = 0.01)。其他临床或疾病参数对疗效无显著影响。复发/难治性b细胞急性淋巴细胞白血病患者对blinatumumab和inotuzumab ozogamicin治疗的反应特点细胞移植9(1):

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Features of response to blinatumomab and inotuzumab ozogamicin therapy in patients with relapse/refractory B-cells acute lymphoblastic leukemia in real clinical practice

included 182 patients with r/r B-ALL, their age was from one to 72 years old. 128 patients were treated with blinatumomab, 54 patients received inotuzumab ozogamicin. Overall response was high in both groups, 96 (75%) and 44 (82%). Th e major predictors of response were adult age (OR= 3.819; 95% CI, 1.744-8.223; p=0.001) and clinical indications, i.e., active disease or measurable residual disease (OR= 0.018; 95% CI, 0.153-0.841; p=0.01). Th e other clinical or disease parameters had no signifi cant impact on response. Features of response to blinatumomab and inotuzumab ozogamicin therapy in patients with relapse/refractory B-cells acute lymphoblastic leukemia in real clinical practice. Cell Th er Transplant 9(1):

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cellular Therapy and Transplantation Medicine-Transplantation

CiteScore

0.60

自引率

0.00%

发文量